GB2544892B - Stable cell lines for retroviral production - Google Patents

Stable cell lines for retroviral production

Info

Publication number
GB2544892B
GB2544892B GB1619643.8A GB201619643A GB2544892B GB 2544892 B GB2544892 B GB 2544892B GB 201619643 A GB201619643 A GB 201619643A GB 2544892 B GB2544892 B GB 2544892B
Authority
GB
United Kingdom
Prior art keywords
cell lines
stable cell
retroviral production
retroviral
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB1619643.8A
Other versions
GB201619643D0 (en
GB2544892A (en
Inventor
Johnson Sabine
Pallant Celeste
Vamva Eirini
Vink Conrad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1520761.6A external-priority patent/GB201520761D0/en
Priority claimed from GBGB1609303.1A external-priority patent/GB201609303D0/en
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of GB201619643D0 publication Critical patent/GB201619643D0/en
Publication of GB2544892A publication Critical patent/GB2544892A/en
Application granted granted Critical
Publication of GB2544892B publication Critical patent/GB2544892B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C12N7/025—Packaging cell lines, e.g. transcomplementing cell lines, for production of virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C12N15/8673—Special methods for packaging systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/00051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/40—Vector systems having a special element relevant for transcription being an insulator
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
GB1619643.8A 2015-11-24 2016-11-21 Stable cell lines for retroviral production Active GB2544892B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1520761.6A GB201520761D0 (en) 2015-11-24 2015-11-24 Stable cell lines for retroviral production
GBGB1609303.1A GB201609303D0 (en) 2016-05-26 2016-05-26 Stable cell lines for retroviral production

Publications (3)

Publication Number Publication Date
GB201619643D0 GB201619643D0 (en) 2017-01-04
GB2544892A GB2544892A (en) 2017-05-31
GB2544892B true GB2544892B (en) 2017-11-15

Family

ID=57354376

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1619643.8A Active GB2544892B (en) 2015-11-24 2016-11-21 Stable cell lines for retroviral production

Country Status (17)

Country Link
US (3) US20170145388A1 (en)
EP (2) EP3380604B1 (en)
JP (1) JP7098521B2 (en)
KR (1) KR102091957B1 (en)
CN (1) CN108291208A (en)
AU (1) AU2016360763B2 (en)
BR (1) BR112018010635A2 (en)
CA (1) CA3006288A1 (en)
DE (1) DE102016122316A1 (en)
ES (2) ES2959326T3 (en)
FR (1) FR3044016A1 (en)
GB (1) GB2544892B (en)
IL (2) IL259254A (en)
IT (1) IT201600117326A1 (en)
RU (1) RU2752498C2 (en)
SA (1) SA518391623B1 (en)
WO (1) WO2017089308A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7816612B2 (en) * 2005-12-21 2010-10-19 Ishida Co., Ltd. Rotary measuring device
RU2749717C2 (en) 2015-11-24 2021-06-16 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Method for temporary transfection for producing retrovirus
GB201706121D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Stable cell lines for retroviral production
GB201715052D0 (en) 2017-09-19 2017-11-01 Oxford Genetics Ltd Vectors
EP3633040B1 (en) 2017-12-22 2023-06-07 Oxford BioMedica (UK) Limited Retroviral vector
EP4017987A4 (en) * 2019-08-23 2023-10-04 Lonza Walkersville, Inc. Methods and constructs for production of lentiviral vector
IL293910A (en) * 2019-12-18 2022-08-01 Lonza Walkersville Inc Methods and constructs for transient production of lentiviral vector
GB202004371D0 (en) 2020-03-26 2020-05-13 Glaxosmithkline Ip Dev Ltd CAR constructs
GB202005096D0 (en) 2020-04-07 2020-05-20 Glaxosmithkline Modified vectors for production of retrovirus
CN113528515B (en) * 2020-04-22 2023-05-05 中国科学院分子植物科学卓越创新中心 CRISPR-Cas13a based technology for interfering and blocking reverse transcription transposition of viruses
CA3183599A1 (en) * 2020-05-15 2021-11-18 Ivexsol, Inc. Compositions and methods for producing stable viral vector producer cells for cell and gene therapy
CN112430582B (en) * 2020-12-04 2022-05-03 北京艺妙神州医药科技有限公司 Stable lentivirus packaging cell line and preparation method thereof
TW202304960A (en) 2021-03-19 2023-02-01 英商葛蘭素史密斯克藍智慧財產發展有限公司 Chimeric antigen receptors targeting claudin-3 and methods for treating cancer
EP4326885A1 (en) * 2021-04-20 2024-02-28 The Regents of the University of California Packaging cells with targeted gene knockouts that improve retroviral vector titers

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003400A1 (en) * 1993-07-23 1995-02-02 Johns Hopkins University School Of Medicine Recombinationally targeted cloning in yeast artificial chromosomes
WO2000065077A1 (en) * 1999-04-22 2000-11-02 The General Hospital Corporation Triple hybrid amplicon vector systems to generate retroviral packaging lines
EP1652932A1 (en) * 2004-11-02 2006-05-03 GBF Gesellschaft für Biotechnologische Forschung mbH Method for the generation of virus producing cell lines and cell lines
WO2008099148A1 (en) * 2007-02-12 2008-08-21 Ark Therapeutics Ltd. Production of lentiviral vectors
WO2013121194A1 (en) * 2012-02-13 2013-08-22 Ucl Business Plc Materials and methods relating to packaging cell lines

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
CZ286979B6 (en) * 1995-06-27 2000-08-16 Bavarian Nordic Res Inst As Capsule encapsulating cells producing viral particles, process of its preparation and pharmaceutical preparation for gene therapy
FR2751223B1 (en) * 1996-07-19 1998-12-04 Rhone Merieux FELIN POLYNUCLEOTIDE VACCINE FORMULA
US6677155B1 (en) * 1999-04-22 2004-01-13 The General Hospital Corporation Triple hybrid amplicon vector systems to generate retroviral packaging lines
AU4559800A (en) * 1999-04-29 2000-11-17 Aarhus Universitet Expression of heterologous genes from an ires translational cassette in retroviral vectors
US20060057553A1 (en) * 2000-05-30 2006-03-16 Estuardo Aguilar-Cordova Chimeric viral vectors for gene therapy
US6689601B2 (en) 2000-09-01 2004-02-10 E. I. Du Pont De Nemours And Company High growth methanotropic bacterial strain
US6586251B2 (en) * 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE10111433A1 (en) * 2001-03-09 2002-09-19 Bundesrepublik Deutschland Let Replication-competent molecular clones of porcine endogenous retrovirus class A and class B, derived from porcine and human cells
NZ545697A (en) 2001-05-30 2008-06-30 Glaxo Group Ltd A lambda-intR mutein comprising a glutamic acid to arginine change at position 174 of Wt lambda-intR
US6835568B2 (en) 2001-10-30 2004-12-28 Virxsys Corporation Regulated nucleic acid expression system
JP4598398B2 (en) * 2002-02-01 2010-12-15 オックスフォード バイオメディカ （ユーケー） リミテッド Virus vector
ATE365220T1 (en) * 2002-11-25 2007-07-15 Bavarian Nordic As RECOMBINANT SMALLPOX VIRUS CONTAINING AT LEAST TWO ATI PROMOTERS
CA2562893A1 (en) * 2004-04-28 2005-11-10 The Trustees Of The University Of Pennsylvania Polyvalent viral vectors and a system for production thereof
PT2088193E (en) * 2004-11-24 2011-02-24 Anaeropharma Science Inc Novel shuttle vector
EP2193879B1 (en) * 2008-12-05 2012-08-01 Mikron Agie Charmilles AG Tool cleaning
RU2577982C2 (en) * 2010-09-02 2016-03-20 МОЛМЕД СпА Semistable production of lentivirus vectors
US9273324B2 (en) * 2010-12-05 2016-03-01 Andrew S. Belmont Recombinant gene expression
WO2012170431A2 (en) * 2011-06-06 2012-12-13 Bluebird Bio, Inc. Improved geneswitch systems
FR2979919B1 (en) * 2011-09-12 2015-12-11 Centre Nat Rech Scient NON-INTEGRATIVE CHIMERIC LENTIVIRAL GENOMES AS INNOVATIVE VACCINES AGAINST HIV-1
EP2895611A4 (en) * 2012-09-14 2016-04-27 Univ California Lentiviral vector for stem cell gene therapy of sickle cell disease
ES2786051T3 (en) * 2012-10-25 2020-10-08 Tocagen Inc Retroviral vector with mini-promoter cassette
WO2015031686A1 (en) * 2013-08-30 2015-03-05 Amgen Inc. High titer recombinant aav vector production in adherent and suspension cells
GB2538321A (en) * 2015-05-15 2016-11-16 Glaxosmithkline Ip Dev Ltd Artificial chromosome for retroviral production
GB2538324A (en) * 2015-05-15 2016-11-16 Glaxosmithkline Ip Dev Ltd Packaging cell line for retroviral production
EP3139086B1 (en) * 2015-09-01 2018-05-23 Philips Lighting Holding B.V. Lighting device with a wireless communication antenna
RU2749717C2 (en) * 2015-11-24 2021-06-16 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Method for temporary transfection for producing retrovirus

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003400A1 (en) * 1993-07-23 1995-02-02 Johns Hopkins University School Of Medicine Recombinationally targeted cloning in yeast artificial chromosomes
WO2000065077A1 (en) * 1999-04-22 2000-11-02 The General Hospital Corporation Triple hybrid amplicon vector systems to generate retroviral packaging lines
EP1652932A1 (en) * 2004-11-02 2006-05-03 GBF Gesellschaft für Biotechnologische Forschung mbH Method for the generation of virus producing cell lines and cell lines
WO2008099148A1 (en) * 2007-02-12 2008-08-21 Ark Therapeutics Ltd. Production of lentiviral vectors
WO2013121194A1 (en) * 2012-02-13 2013-08-22 Ucl Business Plc Materials and methods relating to packaging cell lines

Also Published As

Publication number Publication date
WO2017089308A1 (en) 2017-06-01
EP3380604B1 (en) 2022-12-28
EP3489353A1 (en) 2019-05-29
EP3489353B8 (en) 2023-08-30
US20200123505A1 (en) 2020-04-23
AU2016360763B2 (en) 2020-11-05
RU2018122636A3 (en) 2020-04-02
EP3380604A1 (en) 2018-10-03
ES2939617T3 (en) 2023-04-25
AU2016360763A1 (en) 2018-05-31
IL282603A (en) 2021-06-30
EP3489353B1 (en) 2023-07-26
RU2018122636A (en) 2019-12-25
CN108291208A (en) 2018-07-17
JP2018534937A (en) 2018-11-29
RU2752498C2 (en) 2021-07-28
KR20180079351A (en) 2018-07-10
KR102091957B1 (en) 2020-03-20
FR3044016A1 (en) 2017-05-26
EP3489353C0 (en) 2023-07-26
US20180320147A1 (en) 2018-11-08
BR112018010635A2 (en) 2018-11-27
SA518391623B1 (en) 2022-10-30
US20170145388A1 (en) 2017-05-25
GB201619643D0 (en) 2017-01-04
IL259254A (en) 2018-07-31
IT201600117326A1 (en) 2018-05-21
CA3006288A1 (en) 2017-06-01
GB2544892A (en) 2017-05-31
IL282603B (en) 2022-05-01
JP7098521B2 (en) 2022-07-11
ES2959326T3 (en) 2024-02-23
DE102016122316A1 (en) 2017-05-24

Similar Documents

Publication Publication Date Title
IL282603B (en) Stable cell lines for retroviral production
HK1246825A1 (en) Cell
HK1250667A1 (en) Cell
HK1252162A1 (en) Cell
GB201507368D0 (en) Cell
GB201503500D0 (en) Cell
GB201522097D0 (en) Cells
IL259223B (en) Transient transfection method for retroviral production
HK1215759A1 (en) Electrolyte forming process
HK1215758A1 (en) Electrolyte forming process
GB201603372D0 (en) Cell
GB201706121D0 (en) Stable cell lines for retroviral production
GB201719541D0 (en) Cell Lines
GB201508435D0 (en) Packaging cell line for retroviral production
GB201508425D0 (en) Artificial chromosome for retroviral production
GB201520761D0 (en) Stable cell lines for retroviral production
GB201609303D0 (en) Stable cell lines for retroviral production
PL3560023T3 (en) Electrolyte for lithium-ion-batteries
GB2544891B (en) Transient transfection method for retroviral production
IL252382A0 (en) Oxidant production
GB201520764D0 (en) Transient transfection method for retroviral production
GB201507819D0 (en) Cell
GB201507814D0 (en) Cell
GB201507816D0 (en) Cell
GB201507812D0 (en) Cell